Developing cardiac electrophysiology models for drug safety studies
In plain English
AI plain-English summaryA new generation of computer models is being built to predict how drugs will disrupt the heart's electrical rhythm before they ever reach human volunteers. The problem is that current preclinical safety tests often miss dangerous side effects, forcing regulators to rely on expensive and time-consuming clinical studies called ThoroughQT trials. These mathematical models simulate how multiple ion channels in heart cells respond to a drug, then calculate the risk of arrhythmia. The team is refining shorter, more information-rich experimental protocols to build cell-specific models, then validating those predictions against real experiments. They are also tackling two hard problems: model selection—choosing the right set of equations—and model discrepancy, which quantifies how far a simulation strays from reality. All predictions will be expressed as probability distributions, not single numbers, so regulators can see the uncertainty. If successful, these models could replace the ThoroughQT study entirely, cutting drug development costs and speeding safer medicines to market. The team is already working with pharmaceutical companies and drug regulators to test and roll out the improved models in safety-critical settings.
View original technical description
View the original record at the funder ↗
Researchers
Related Research
Grants with similar aims, by meaning.
Original classification
Senior Research Fellowship BasicPlain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research. Is something wrong? Let us know